More News

Emerging Companies Pursuing Ophthalmic Indications, March 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Poll of MDs and ODs, March 2026

March 2026 Ophthalmic News Briefs

STAAR Surgical announced Feb. 17 that the US FDA had approved an expanded age indication for Evo and Evo+ implantable Collamer lenses (ICLs), extending their use from patients 21 to 45 years old to...

Alcon, Lensar Scrap Acquisition Deal in Face of FTC Opposition

Alcon and Lensar reported March 16 that they were terminating Alcon’s $430 million acquisition of the cataract laser company, in the wake of opposition from the US Federal Trade Commission (FTC). L...

US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures

Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment for dry e...

Glaukos Launches Epioxa Epi-On Crosslinking Therapy for Keratoconus

Glaukos announced March 19 that its Epioxa, an epi-on version of the company’s corneal crosslinking therapy for keratoconus, was available to order directly from Glaukos or through its specialty ph...

New Law in Kansas Expands ODs’ Scope to Include Laser

Kansas has become the 15th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. House Bill 2223, signed into law by Gov. Laura Kelly on March 12, ...

Formycon Settlement Clears Way for Eylea Biosimilar in Europe, Other Markets

German companies Formycon and Klinge Biopharma reported March 19 that they had reached a settlement and license agreement with Regeneron and Bayer that clears the way for commercialization of Ahzan...

Super Vision Gains China Approval of i-NYS Implant for Congenital Nystagmus

China-based Super Vision reported March 16 that its i-NYS implantable device forcongenital nystagmus had received market approval from China’s National Medical Products Administration (NMPA). Super...

Amydis Wins $2.5 Million NIH Grant to Advance Retinal Tracer for ALS

Amydis, of San Diego, California, announced March 11 that it had been awarded $2.5 million from the National Institutes of Health (NIH) to advance a retinal tracer that could foster earlier detecti...

Heru’s New PretestPro for VR Headset Runs Four Visual Exams in Under 2 Minutes

Ophthalmic wearable diagnostic company Heru recently unveiled its PretestPro, which the company says can run four visual exams in under two minutes. The company showcased the system March 11-14 at ...

J&J Vision Gains US FDA Approval for Tecnis PureSee EDOF IOL

Johnson & Johnson Vision announced March 12 that it had gained US FDA approval for the Tecnis PureSee, an extended depth of focus (EDOF) intraocular lens (IOL) for use in cataract surgery. The Jack...

2025 Ophthalmic Revenue Roundup for STAAR Surgical and Sight Sciences

STAAR Surgical reported March 3 that its net sales in 2025 were $239.4 million, a 23.7 percent decline from $313.9 million in 2024. Q4-2025 net sales were $57.8 million, an 18.1 percent increase ov...

US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data

Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...

Lenz Submits Marketing Application for Vizz Presbyopia Drop in Europe

Lenz Therapeutics announced March 10 that it had submitted a marketing authorization application to the European Medicines Agency for Vizz, an eye drop targeting presbyopia. Vizz (aceclidine ophtha...

Aravind Eye Surgeons Named as 2026 Chang-Crandall Humanitarian Award Recipients

The ASCRS Foundation Board announced Feb. 5 that it had selected Aravind Haripriya, MD, and Rengaraj Venkatesh, MD, as the recipients of its 2026 Chang-Crandall Humanitarian Award. The honor was es...

Rayner Expands US Headquarters in Memphis Amid Milestone Successes

Rayner reported March 9 that it had opened a new 10 thousand-square-foot facility in Memphis, Tennessee, which will serve as its expanded US headquarters. The UK-based company said the move signifi...

Glaucoma Research Foundation Awards Record $3.06 Million in Annual Research Grants

The Glaucoma Research Foundation announced March 9 that it would distribute a record total of $3.06 million in annual research grants to support innovative research in glaucoma and neurodegeneratio...

Cassini Gains MDR Approval for Surgical Guidance System in the EU

Cassini Technologies, of the Netherlands, announced March 5 that its intraoperative guidance system for ophthalmic surgery had gained EU marketing authorization under the Medical Device Regulation ...

Qlaris Bio Appoints Fred Guerard, PharmD, as President and CEO

Qlaris Bio announced March 10 that it had appointed Fred Guerard, PharmD, as president and chief executive officer, effective March 1. Guerard will also join the company’s board of directors. He mo...

Virtual Field, Maker of VR Perimetry Headsets, Rebrands as Carrot

Virtual Field, a pioneer in virtual reality (VR) headsets for perimetry, announced March 11 that it was rebranding as Carrot. The Brooklyn, New York, company said its automated platform now perform...

Oertli Launches OS 4 Up Dual-Function Cataract-Vitrectomy System

Switzerland-based Oertli announced Feb. 23 that its OS 4 Up dual-function cataract/vitrectomy machine is now available in all CE-certified markets. Features include adaptive energy delivery with Ph...

Ophthalmic Quarterly and 2025 Revenue for Carl Zeiss Meditec, Harrow, RxSight, ANI, and Xbrane

Million Carl Zeiss Meditec reported Feb. 12 that ophthalmology revenue for the last three months of 2025, the first quarter of its fiscal year 2025/2026, totaled €356.9 million ($419.2 million, con...

Rayner Acquires Distribution Rights to Anikavisc OVD in US

UK-based Rayner reported March 2 that it had acquired the US distribution rights to Anikavisc, an ophthalmic viscosurgical device (OVD), from Japan’s Visco Technologies Inc. Anikavisc, a cohesive f...

US FDA Gives Green Light to Phase III Trial of Harrow’s Triesence for Post-op Inflammation and Pain

Nashville, Tennessee-based Harrow reported on March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase III trial of Tri...

Alcon-Lensar Deal Now Expected to Close in First Half of 2026

Alcon’s acquisition of Lensar is now on track to close in the first half of 2026, subject to customary conditions, including receipt of regulatory approval from the US Federal Trade Commission, Len...

US FDA Gives Green Light to Phase I/II Trial of Sanaregen’s Retinal Cell Therapy Candidate

Sanaregen Vision Therapeutics reported March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of its retin...

Sandoz Reports EU Approval for Ranibizumab Biosimilar Branded Ranluspec

Swiss drugmaker Sandoz announced Feb. 23 that the European Commission had granted marketing authorization for Ranluspec, a ranibizumab biosimilar developed by India’s Lupin Limited. Sandoz holds ex...

Cirrus Expands to Singapore, Unveils GA Cell Therapy Candidate

Cirrus Therapeutics reported March 3 that it had established an R&D site in Singapore, expanding its presence in the Asia-Pacific region. The Cambridge, Massachusetts, company also unveiled a secon...

Axol Bioscience Acquires Ophthalmology Business from Newcells Biotech

UK-based Axol Bioscience, a provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, reported Feb. 18 that it had acquired the ophthalmology business of Newcel...

EyeMD Electronic Health Records Platform Rebrands as Optivate

EyeMD EMR Healthcare Systems and its billing subsidiary Abillifeye announced March 3 that they would rebrand as Optivate and launch a new website, optivatehealth.com. Optivate, of Bonita Springs, F...

US FDA Accepts sNDA for Opus’ Presbyopia Candidate, Sets PDUFA Date of Oct. 17, 2026

Commercial partners Viatris and Opus Genetics reported Feb. 25 that the US FDA had accepted the supplemental new drug application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%), targeti...

2025 Ophthalmic Revenue Roundup for Alcon, Apellis, Tarsus, and Immunocore

Alcon reported Feb. 24 that its full year 2025 net sales totaled $10.3 billion, a 5 percent increase over $9.8 billion in 2024. Q4-2025 sales were $2.7 billion, a 9 percent increase over $2.5 billi...

Children’s Hospital Los Angeles Pioneers Aqueous Biopsy Test for Ocular Cancer

Researchers at Children’s Hospital Los Angeles (CHLA) have developed a liquid biopsy test of aqueous humor that they say can significantly improve the diagnosis and clinical management of tumors in...

G360 Meeting Sets Fundraising Record, Shines Spotlight on Range of Stakeholders

The 2026 Glaucoma 360 meeting set a record for fundraising, with its gala taking in $715 thousand in donations and the New Horizons Forum bringing in another $462 thousand from corporate sponsorshi...

Outlook Grants Mediconsult Rights to Market Lytenava in Switzerland

Outlook Therapeutics announced Feb. 19 an agreement granting Mediconsult exclusive commercial distribution rights for Lytenava (bevacizumab gamma) in the Swiss market. Financial details were not di...

HelpMeSee Launches Simulation-Based MSICS Training Centers in Ghana, Nigeria

Global nonprofit group HelpMeSee announced in February that it had opened new virtual training centers for manual small incision cataract surgery (MSICS) in Ghana and Nigeria. Both training centers...

Formosa Licenses Clobetasol Drops to Arrotex for Australia, New Zealand

Taiwan-based Formosa Pharmaceuticals announced Feb. 23 that it had agreed to license to Arrotex Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inf...

US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate

NexEos Bio, of Malvern, Pennsylvania, reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial...

US FDA Gives Green Light to Phase II Trial of Cloudbreak’s Presbyopia Drop Candidate

The financial website TipRanks reported on Feb. 15 that the US FDA had signed off on Cloudbreak Pharma’s investigational new drug (IND) application, allowing the company to proceed with a Phase II ...

Surging Economy, Aging Population to Fuel Growth in India’s Ophthalmic Market through 2030

India’s ophthalmic market is poised for strong growth over the next five years. The market will continue to expand across key ophthalmic subspecialties through 2030, according to Market Scope’s for...

Dropless Cataract Surgery Gets a Boost as Interest, Data Align

Dropless cataract surgery continues to gain traction as surgeons seek to simplify postoperative care and im-prove patient adherence—but the meaning and adoption of the practice vary significantly. ...

US FDA Approves Re-administration of Glaukos’ iDose TR

Glaukos announced Jan. 28 that the US FDA had approved a supplement to its new drug application allowing for re-administration of iDose TR, the company’s intracameral travoprost implant for glaucom...

$Nidek Launches Phantom Open-Field Refraction System$

Nidek Launches Phantom Open-Field Refraction System

Japanese company Nidek reported Jan. 26 that it had launched the Phantom Open-Field Refractive System. An open-field system eliminates the traditional phoropter in front of the patient; instead, vi...

Select US FDA Approvals and Clearances in January 2026

The US FDA’s ophthalmic device division granted clearance to one device using the 510(k) pathway in January 2026, according to the agency’s database. Phelcom Technologies received clearance for its...

PDUFA Dates for Ophthalmic Drug Candidates, February 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Approves Tenpoint’s Yuvezzi Drops for Presbyopia

Tenpoint Therapeutics announced Jan. 28 that the US FDA had approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia. The company said it expects to launc...

BioAge Leads Latest Ophthalmic Fundraising with $115 Million Offering

BioAge led recent ophthalmic fundraising efforts with a $115 million upsized public offering to advance an oral treatment candidate for DME. Financing announced in the past four weeks totaled $308....

New US Law Institutes Major Pharmacy Benefit Manager Reforms in 2029

The $1.2 trillion US spending package signed into law on Feb. 3 includes major reforms to pharmacy benefit manager (PBM) practices. These provisions go into effect for health plan years that come a...

Market Scope’s G360 Attendee Survey Looks at Patient Fears over Laser Therapy

Market Scope conducted an online survey of Glaucoma 360 meeting attendees in January and February as part of our 11-year partnership with the Glaucoma Research Foundation for its annual meeting. Th...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.